Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 61 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2014', provides an overview of the Peripheral Neuropathy (Sensory Neuropathy)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Peripheral Neuropathy (Sensory Neuropathy)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Peripheral Neuropathy (Sensory Neuropathy) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Peripheral Neuropathy (Sensory Neuropathy) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Peripheral Neuropathy (Sensory Neuropathy) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Peripheral Neuropathy (Sensory Neuropathy) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Peripheral Neuropathy (Sensory Neuropathy) Overview 7
Therapeutics Development 8
Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) - Overview 8
Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis 9
Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics under Development by Companies 10
Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics under Investigation by Universities/Institutes 11
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Peripheral Neuropathy (Sensory Neuropathy) - Products under Development by Companies 14
Peripheral Neuropathy (Sensory Neuropathy) - Products under Investigation by Universities/Institutes 15
Peripheral Neuropathy (Sensory Neuropathy) - Companies Involved in Therapeutics Development 16
Pfizer Inc. 16
Neuren Pharmaceuticals Limited 17
Paladin Labs Inc. 18
RegeneRx Biopharmaceuticals, Inc. 19
INSYS Therapeutics, Inc. 20
Regenesance BV 21
Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
RGN-352 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
AL-309 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
NNZ-2591 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
NRP-2945 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
GL-2045 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules for Oncology, CNS and Metabolic Disorders - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Synthetic Peptides for Peripheral Neuropathy - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Peptides for Neuropathic Pain and Peripheral Neuropathy - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules to Inhibit Cysteine Protease for Oncology, Immunology and CNS Disorders - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Peptide to Activate GIPR for CNS, Metabolic Disorders and Trauma - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Cannabidiol - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
BCPN-03 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
MAC Complex Program - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Peripheral Neuropathy (Sensory Neuropathy) - Recent Pipeline Updates 48
Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects 52
Peripheral Neuropathy (Sensory Neuropathy) - Discontinued Products 53
Peripheral Neuropathy (Sensory Neuropathy) - Product Development Milestones 54
Featured News & Press Releases 54
Jul 12, 2013: Neuren Receives Notice of Allowance for Two New Patents 54
Jul 12, 2013: Neuren Receives Notice of Allowance for New Patent 54
Dec 10, 2012: Spinifex Pharma Starts Phase II Proof-of-concept Trial Of EMA401 In Chemotherapy-induced Peripheral Neuropathy 55
Feb 07, 2011: EpiCept Reports Positive Results From EpiCept NP-1 Trial In Patients With Chemotherapy-Induced Peripheral Neuropathy 56
Sep 08, 2010: DARA Announces Phase III Trial Results Of KRN5500 In Patients With Chemotherapy Induced Peripheral Neuropathy And Advanced Cancer 56
Jun 11, 2010: Pfizer, Eisai to launch postherpetic neuralgia drug Lyrica Capsules on June 22 57
Jun 11, 2010: Pfizer, Eisai to launch postherpetic neuralgia drug Lyrica Capsules on June 22 57
Apr 06, 2010: Pfizer told to Pay $142.1 million for Neurontin marketing violations. 57
Feb 24, 2010: Allon Reports Preclinical Efficacy Data Of AL-309 For Treatment Of Peripheral Neuropathy 58
Nov 18, 2009: NeoPharm Presents LE-DT Phase I Data At The AACR Conference 58
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 61
Disclaimer 61

List of Tables
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H2 2014 8
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Pfizer Inc., H2 2014 16
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Neuren Pharmaceuticals Limited, H2 2014 17
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Paladin Labs Inc., H2 2014 18
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2014 19
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by INSYS Therapeutics, Inc., H2 2014 20
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Regenesance BV, H2 2014 21
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 26
Number of Products by Stage and Route of Administration, H2 2014 28
Number of Products by Stage and Molecule Type, H2 2014 30
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics - Recent Pipeline Updates, H2 2014 48
Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects, H2 2014 52
Peripheral Neuropathy (Sensory Neuropathy) - Discontinued Products, H2 2014 53